Sign inJoin
Company / Finance

uniQure N.V.

QURE · NASDAQ

uniQure has a gene-therapy platform and clinical pipeline, but the latest filings show small revenue, large research spending, operating losses and a balance sheet that must fund trials through binary data and regulatory events.

FollowAdd to WatchlistAsk Question
NASDAQQURECoverage BootstrapuniQure N.V.
Latest ReportMay 20, 2026uniQure: the gene-therapy runway is still burning cashView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

uniQure: the gene-therapy runway is still burning cash

uniQure has a gene-therapy platform and clinical pipeline, but the latest filings show small revenue, large research spending, operating losses and a balance sheet that must fund trials through binary data and regulatory events.

May 20, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
uniQure N.V.the gene-therapy runway is still burning cashMay 20, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
uniQure: the gene-therapy runway is still burning cashuniQure has a gene-therapy platform and clinical pipeline, but the latest filings show small revenue, large research spending, operating losses and a balance sheet that must fund trials through binary data and regulatory events.NASDAQMay 20, 2026Research reportReadSlides